$TPST News

Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets Expertise

Tempest Therapeutics Files Prospectus Registering Resale Of Up To 9,534,164 Shares Of Common Stock

HC Wainwright & Co. Maintains Buy on Tempest Therapeutics, Lowers Price Target to $7

Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors

Tempest Therapeutics (TPST) Stock Surges Wednesday: What's Driving the Action?

Tempest Therapeutics (TPST) Stock Climbs Over 66% After Hours: Here's Why

Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform

Tempest Therapeutics Announces Up to $7.5 Million Private Placement

Tempest Therapeutics Commences ~$2.5M Offering Of 3.106M Common Shares At $0.805 Per Share

Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Tempest Therapeutics Says Justin Trojanowski To Resign As Principal Financial Officer Effective Sept 1; Nicholas Rossettos Appointed As CFO, Principal Financial Officer

Tempest Therapeutics Files Prospectus Related To The Offer And Sale Of Up To 8,910,579 Shares Of Common Stock

Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update

Tempest Therapeutics Secures $50M Equity Purchase Agreement With Lincoln Park Capital

Tempest Therapeutics Q2 EPS $(0.34) Misses $(0.30) Estimate

Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T

Tempest And Senlang To Collaborate To Develop Tempest’s Proprietary TPST-4003 Product Candidate, Beginning With IIT In China Evaluating TPST-4003 In ~10 Patients With MG Or MS; Expects First Patient Enrollment And Dosing To Occur In Q4 Of 2026

Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026

Tempest Unveils Next-Gen In Vivo CAR-T Platform; To Advance TPST-4003 Into Q4 2026 Trial In MG, MS Patients

Tempest Therapeutics Files Prospectus For Offering 2.427M Common Shares On Behalf Of Selling Shareholders